Clinically Proven Care for Dry Age-Related Macular Degeneration
MacuMira is Canada’s first clinically proven, regulatory-approved light therapy designed for patients living with dry age-related macular degeneration (AMD). This noninvasive treatment is available through Warman Eyecare, with care provided in collaboration with our InVision Eyecare location in Saskatoon.
Dry AMD can make everyday tasks such as reading, driving, and recognizing faces more difficult over time. MacuMira is designed to support macular function, improve visual performance, and enhance quality of life for eligible patients.
If you have been diagnosed with dry AMD, this treatment may offer a new option to help support your vision. Contact us to schedule your consultation today.
Understanding Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, the central part of the retina responsible for sharp, detailed vision.
Many eye diseases, including AMD, may not show noticeable symptoms in the early stages. Regular eye exams are essential for early detection and management. During an eye exam, we assess for signs of AMD and provide education on reducing risk factors and supporting long-term eye health.
What Is Dry AMD?
Dry AMD is the most common form of age-related macular degeneration. It occurs when small deposits called drusen build up in the macula or when age-related changes affect the retinal tissue.
As it progresses, dry AMD can lead to:
- Blurry or distorted central vision
- Difficulty seeing in low light
- Reduced colour clarity
- Decreased contrast sensitivity
AMD is one of the leading causes of vision loss in adults over 50.
What Is Wet AMD?
Wet AMD, also known as neovascular AMD, occurs when abnormal blood vessels grow beneath the retina. These vessels can leak fluid or blood and cause more rapid vision loss.
Treatment options for wet AMD may include:
- Eye injections to reduce abnormal blood vessel growth
- Laser procedures to target affected vessels
- Combination therapies in certain cases
Early detection is critical to help preserve vision.
Benefits of MacuMira Treatment
MacuMira is a noninvasive light therapy designed to support visual function in patients with early to intermediate dry age-related macular degeneration. Potential benefits may include:
- Improved central vision in eligible patients
- Enhanced contrast sensitivity and clearer vision in low-light conditions
- Reported visual improvements within the first few weeks for some patients
- Support for overall macular function as part of a broader care plan
MacuMira is intended to help support visual performance in dry AMD when conventional options are limited.
Who May Be a Candidate for MacuMira
MacuMira is not suitable for everyone, and a proper eye examination is required to determine eligibility. This treatment may be considered for patients who:
- Have a confirmed diagnosis of dry age-related macular degeneration
- Are in the early to intermediate stages of the condition
- Have noticed gradual changes in central vision related to AMD
- Are seeking noninvasive options as part of their eye care plan
A comprehensive assessment at Warman Eyecare will help determine whether MacuMira is appropriate for your specific needs.
Supporting Macular Health in Dry AMD
Alongside MacuMira treatment, your optometrist may recommend supportive strategies such as:
- Healthy lifestyle habits, including not smoking
- A nutrient-rich diet that supports eye health
- Vitamins and antioxidants, including vitamin C, vitamin E, zinc, lutein, zeaxanthin, and Omega-3 fatty acids
- Personalized recommendations based on your stage of AMD
For some patients, beta carotene may not be recommended due to increased health risks in those with a history of smoking.
MacuMira is an in-clinic, noninvasive treatment option designed to support visual function in early to intermediate dry AMD.
Ask About MacuMira for Dry AMD
Looking for noninvasive treatment options for dry age-related macular degeneration (AMD)? We offer MacuMira at our InVision Eyecare location in Saskatoon.
If you’re interested in learning whether MacuMira is right for you, speak with your optometrist during your next eye exam. They can assess your eyes and, if appropriate, refer you to our InVision team for further care.
Frequently Asked Questions About AMD and MacuMira
MacuMira is a noninvasive, clinically proven light therapy designed to support visual function in patients with early to intermediate dry age-related macular degeneration.
No. MacuMira does not cure dry AMD. It is designed to help support visual function and quality of life in patients with the condition.
It is intended for patients diagnosed with early to intermediate dry AMD. A full eye examination is required to determine eligibility.
MacuMira uses targeted light therapy designed to stimulate retinal function and support the macula, which is responsible for central vision.
Treatment protocols vary, and your optometrist will outline a schedule based on your individual needs and stage of AMD.
No. MacuMira is a noninvasive and comfortable in-clinic treatment.
Some patients report visual improvements within the first few weeks of treatment, although results vary from person to person.
Coverage varies depending on the provider and plan. Our team can review your benefits and provide guidance on billing options.
Yes. Regular eye exams are important to monitor AMD progression and overall eye health.
MacuMira is provided through Warman Eyecare in collaboration with our InVision Eyecare location in Saskatoon.
Come Visit Us in Warman
Warman Eyecare is worth the visit! Stop in to say hi and to meet our staff. We’re down the street from the high school on Klassen Street and 6th Avenue, directly behind the Tim Hortons.
Our Address
Contact Information
- Phone: 306-700-3576
- Fax: 306-242-8674
- Email: wecadmin@yxevision.ca
After Hours Emergencies: 306-371-9911
Hours of Operation
*Closed, but we’d be happy to see you at Stonebridge Eyecare, Broadway Eyecare, Brighton Eyecare, or InVision Eyecare!
A Look
Inside Warman Eyecare
See What Our Patients Are Saying
